English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

The number of treatment options for metastatic castration‐resistant prostate cancer has increased in recent years. Abiraterone, which selectively inhibits  CYP 17 in the androgen synthesis pathway, is widely used. Liver metastasis is one of the worst prognostic factors in metastatic castration‐resistant prostate cancer. Only a few case reports have shown abiraterone successfully treated the liver metastasis of metastatic castration‐resistant prostate cancer.    Case presentation  A 62‐year‐old man with prostate‐specific antigen of 16.69 ng/mL was diagnosed with Gleason 8 (3 + 5) poorly differentiated prostate adenocarcinoma. Androgen deprivation therapy and sequential anti‐androgen replacement were performed; however, the disease advanced to castration‐resistant prostate cancer with liver metastasis. Prior to docetaxel, abiraterone achieved marked improvements in liver metastasis and prostate‐specific antigen.    Conclusion  Metastatic castration‐resistant prostate cancer patients with visceral metastasis were excluded from  COU ‐ AA ‐302, which is phase  III  trial on abiraterone prior to docetaxel. Although docetaxel is the recommended treatment for the visceral metastasis of castration‐resistant prostate cancer according to the  European Association of Urology  guidelines, abiraterone also has potential as a treatment option.

Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis